| Basics |
Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals Inc is a company focused on the development of novel compounds for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH).
|
| IPO Date: |
February 6, 2007 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$13.11B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$3.78 | 2.57%
|
| Avg Daily Range (30 D): |
$11.79 | 2.35%
|
| Avg Daily Range (90 D): |
$8.66 | 1.97%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.21M |
| Avg Daily Volume (30 D): |
.32M |
| Avg Daily Volume (90 D): |
.3M |
| Trade Size |
| Avg Trade Size (Sh.): |
43 |
| Avg Trade Size (Sh.) (30 D): |
25 |
| Avg Trade Size (Sh.) (90 D): |
27 |
| Institutional Trades |
| Total Inst.Trades: |
2,398 |
| Avg Inst. Trade: |
$6.32M |
| Avg Inst. Trade (30 D): |
$15.42M |
| Avg Inst. Trade (90 D): |
$15.16M |
| Avg Inst. Trade Volume: |
.03M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$6.78M |
| Avg Closing Trade (30 D): |
$18.73M |
| Avg Closing Trade (90 D): |
$17.08M |
| Avg Closing Volume: |
32.79K |
|
|
| Financials |
| |
TTM |
Q2 2025 |
Q1 2025 |
|
Basic EPS
|
$-5.08
|
$-1.9
|
$-3.32
|
|
Diluted EPS
|
$-5.08
|
$-1.9
|
$-3.32
|
|
Revenue
|
$ 287.27M
|
$ 212.8M
|
$ 137.25M
|
|
Gross Profit
|
$
|
$
|
$ 132.74M
|
|
Net Income / Loss
|
$ -114.19M
|
$ -42.28M
|
$ -73.24M
|
|
Operating Income / Loss
|
$ -113.98M
|
$ -47.2M
|
$ -79.31M
|
|
Cost of Revenue
|
$
|
$
|
$ 4.51M
|
|
Net Cash Flow
|
$ 109.5M
|
$ 2.55M
|
$ 83.63M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Jul 25, 2016:
1:35
|
|
|
|
